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[NTERLEUKIN-5 (IL-5) is a cytokine that pre-
ferentially effects the development and function
ofeosinophils, and is considered important in the
pathophysiology of allergic inflammation. In this
study, we evaluated the ability of recombinant
human IL-5 (rHu IL-5) to promote tissue eosino-
philia and the importance of this eosinophilia to
pathological alterations in vascular function.
Repetitive subcutaneous administration for 18
days ofrHu IL-5 resulted in a 7-fold increase in the
number of eosinophils found in the ipsilateral
hamster cheek pouch membrane. The con-
tralateral cheek pouch membrane and peritoneum
of these animals showed lesser but significant ele-
vations in the number of eosinophils. In contrast,
denatured rHu IL-5 did not elevate eosinophils in
these tissues. Through the use of intravital micro-
scopy and fluorometric analysis, rHu IL-5 treated
hamster cheek pouch membranes were evaluated
for alterations in microvascular permeability,
using plasma clearance of FITC-dextran 150 as an
index. Despite promoting a prominent tissue eosi-
nophilia, the repetitive subcutaneous injections of
rHu IL-5 did not alter the clearance of FITC-
dextran 150. Topical application of rHu IL-5 to the
cheek pouch, also, had no effect on the clearance
of FITC-dextran 150. Immunofluorescence obser-
vations using an antibody to the granule protein,
eosinophil peroxidase, indicated that the recrui-
ted cells had not degranulated. Our results support
the importance of IL-5 in the recruitment of tissue
eosinophils, but further stimulation is probably
required to cause degranulation of these cells and
the ensuing tissue damage.
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Introduction
Elevated numbers of eosinophils in the blood
and tissues is a common feature associated with
allergic reactions.1-3 Through the generation of
inflammatory lipid mediators, like platelet activat-
ing factor (PAF) or leukotrienes, and the release
of biologically active granule proteins, the eosino-
phil leukocyte has been documented as a potent
effector cell capable of contributing to the patho-
physiology of allergic disorders.4-C-In support of
this hypothesis, we and others have shown that
eosinophil granule proteins can cause increased
vascular macromolecular permeability, which may
lead to oedema.7’a
Cytokines such as granulocyte-macrophage
colony stimulating factor (GM-CSF) and the
interleukins (IL) 3 and 5 have been identified as
agents that may enhance eosinophil function ,in
91o allergic inflammatory reactions.’ Recent experi-
ments have documented that IL-5 is the pre-
dominant cytokine that can cause the preferential
proliferation, differentiation, and tissue recruit-
ment of eosinophil leukocytes.11’12 Furthermore,
IL-5 affects the activation, chemotatic responses,
degranulation, and decreased apoptosis of per-
13- 15 ipheral blood derived eosinophils.
Because IL-5 possesses biological activity
across species, we used recombinant human IL-5
to induce eosinophilia in the Syrian hamster.’7
In order to investigate whether cytokine-induced
tissue eosinophilia promotes oedema, we used
the plasma clearance of fluoroscein isothio-
cyanate (FITC)-dextran 150 in the hamster cheek
pouch preparation as a measure of changes in
vascular permeability.
Materials and Methods
The male golden Syrian hamsters (80-100g)
used for these experiments were cared for in
accordance with the guidelines of the Animal
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Care and Use Committee of both the University Fisher Leukostat stain. A total of 300 cells under
of Medicine and Dentistry of New Jersey and 400 x magnification were counted and the differ-
Schering-Plough Research Institute, and the NIH ential was recorded.
Guide for the Care and Use of Laboratory To evaluate the effect of rHu IL-5 on eosino-
Animals (NIH Publication No. 86-23). Animals phil influx into the cheek pouch membrane,
were permitted unrestrained access to food and hamsters received repetitive injections of 0.01 mg
water, of denatured or native rHu IL-5 in 0.1 ml of saline
(Schering-Plough Research Institute, Kenilworth,
Enumeration of eosinophils: In the studies NJ). The It-5 was denatured by boiling a lmg/ml
designed to measure eosinophil infiltration into solution for 5 min, without loss of soluble
the cheek pouch, hamsters were euthanized by protein. These injections were given on alternate
COg asphyxiation. The oral surfaces of both days with a maximum of three injections per
cheek pouches were rinsed with normal saline, week. This resulted in a total of seven injections
the membranes were surgically removed, stret- of rHu IL-5 for the 18-day period or four injec-
ched and stapled to a white index card. Mounted tions for the 9-day paradigm. Injections were
membranes were fixed in phosphate buffered given subcutaneously to one cheek. Particular
formalin (Fisher, Fairlawn, NJ). Using a number 6 care was taken to avoid puncturing the under-
ear-punch, sections of cheek pouch membranes lying cheek pouch membrane. Treated animals
were removed and stained for eosinophils using were then returned to their cages.
the method of Duffy eta/.18 Regions distant from
blood vessels were chosen for examination using Macromolecular clearance and intravital micro-
100 x magnification. From each tissue (n 3) scopy: To assess the integrity of the microcircula-
per treatment group, at least five random fields tion following various treatments, separate sets of
were chosen using 400 x magnification and the hamsters were anaesthetized with sodium pento-
number of eosinophils measured. The data per barbital (60mg/kg, i.p.) and tracheotomy Was
treatment group were compiled and expressed performed. The fight jugular vein was cannulated
as the mean number of eosinophils/high power for the administration of the fluorochrome tracer
field (#/HPF; n 15). and supplemental doses of i.v. anaesthetic. The
Eosinophil recruitment and degranulation in fight carotid artery was cannulated for collection
the cheek pouch membrane was assessed using of arterial blood samples. The cheek pouch was
an immunofluorescence technique. Membrane prepared according to previously published
tissue samples were cut into 5 btm sections and methods.8’21’22 Briefly, a two-piece Lucite
subsequently stained with rabbit anti-human chamber with a 1-ml reservoir capacity was
eosinophil peroxidase (anti-EPO; unpurified anti- attached to a single layer of the pouch, delineat-
serum diluted 1:20). This antiserum was devel- ing a 2.3cm
2 area for intravital microscopy. The
oped in our laboratory using purified human chamber reservoir was filled with bicarbonate
eosinophil peroxidase as described previously.19 buffer (131.9mM NaCl, 4.7mM KCl, 2.0mM
Species cross-reactivity with the antiserum was CaCI2, 1.2mM MgSO4 and 18.0mM NaHCO3; pH
confirmed on hamster eosinophils obtained from 7.35) equilibrated with 5% CO2 in 95% N2.
peritoneal lavage. No reactivity of these tissues Throughout the surgery and experimental proto-
with normal rabbit serum was found (data not col, animals were kept on a heating pad to main-
shown). Indirect fluorescence microscopy and tain body temperature at 37C.
photography was performed using an affinity Macromolecular clearance from the cheek
purified FITC-labelled goat anti-rabbit IgG pouch was measured using the plasma clearance
(Southern Biotechnology Associates, Birmingham of FITC-dextran (MW 150000; Sigma Chemical
AL). Samples were then stained in haematoxylin Co., St Louis; FITC-dx 150) as described pre-
and eosin for leukocyte identification.
2 Prepara- viously.’2 After surgical preparation, the hamster
tion and analysis were performed without prior was positioned on a lucite board mounted on
knowledge of the treatment applied, the stage of a Nikon Optiphot microscope. A 1 h
To obtain peritoneal eosinophils, the perito- stabilization period followed the surgery, during
neum was lavaged with 10ml of normal saline which the pouch was continuously suffused with
and the accompanying cells were recovered using bicarbonate buffer (1 ml/min; 37C).
a Jelco Teflon catheter (Critikon, Tampa, FL). FITC-dx 150 was injected as a bolus (100mg/
Cells were centrifuged at 200 x g for 15 min at kg, i.v.) 30 min into the stabilization period. This
5C. Cell pellets were then resuspended in 2 ml was followed by the continuous infusion of
of phosphate buffered saline (Gibco, Grand FITC-dx 150 (0.15mg/kg/min) for the duration
Island, NY) with 0.1% foetal calf serum. Slides of the study. Blood samples were collected every
from cytospin preparations were visualized with 30 min from the arterial cannula. In order to
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determine plasma clearance values, suffusate
samples and plasma levels of FITC-dx 150 were
determined according to previously published
methods.
8 To evaluate the possible direct
effects of IL-5 on the microcirculation, rHu IL-5
(0.1 mg/ml, I ml total volume) was topically
applied to separate cheek pouch preparations as
described previously.
8 Briefly, topical application
of IL-5 was conducted by interruption of the suf- .:
fusate, aspiration of the residual bicarbonate
buffer, application of the IL-5 solution by a 1 ml
syringe to the chamber reservoir, and by incuba-
tion for 5 min. All solutions were warmed to
35C for 5 min prior to application. After appli-
cation the IL-5 solution was aspirated, the
chamber bed washed three times (3 x I ml) with
bicarbonate buffer (35C) and the suffusate re-
[] denatured rHu IL-5
native rHu IL-5
4 9 11 16 18
established. Day
Intravital microscopy of the cheek pouch FIG. 1. Time-course of rHu IL-5 induced eosinophilia in the ipsi- membrane was performed using a Nikon Opti- lateral hamster cheek pouch membrane. Animals received repeti-
phot microscope with 6.3 x, 10 x 20 x, and tive subcutaneous injections of either native or denatured rHu IL-
32 x long-working distance Leitz objectives with 5 as described in Materials and Methods. Membranes were
removed, fixed and processed for histological evaluation. Eosino- 10 x Nikon oculars.8’2’2 The microscope was phils were enumerated in five microscopic fields under 400x
equipped for transillumination and epi-illumina- magnification. Each treatment group had three animals per day
tion. Brightfield transillumination was provided (n.d. not done). Data reported are the mean eosinophil number
by a fibre optic probe inserted into the pouch,
per high power field (#/HPF)+ S.E.M. Significance (*)between
treatments, within the given day, was determined using the
The probe was connected to a 100W halogen Mann-Whitney non-parametric test, with p< 0.05.
lamp. Epi-illumination was provided by a 50W
mercury arc lamp, with appropriate filters for
fluorescence. The recording system consisted of animals treated with denatured rHu IL-5 devel-
a CCD camera (Dage, Michigan City, IN) con- oped a marginal eosinophilia in the ipsilateral
nected to a Panasonic time generator, a Sony VO cheek pouch membrane only (Fig. 1).
5858 videotape recorder, and a RCA mono- Examination of eosinophil numbers in the
chrome video monitor. In order to minimize contralateral cheek pouch membranes after rHu
untoward effects from fluorescence epi-illumina- IL-5 treatment revealed a small but significant
tion, viewing was kept to less than 45 s.23 increase over 18 days of therapy (Fig. 2).
However, eosinophil numbers were considerably
Statistical analysis: All values presented are mean less than those in the ipsilateral cheek pouch
_+ S.E.M. Statistical significance (p < 0.05) was membrane. There was no significant increase in
determined using the non-parametric, one-tailed, the recruitment of eosinophils to the con-
Mann-Whitney test (InstatTM, GraphPad, San tralateral membrane in denatured rHu IL-5
Diego, CA). treated animals (Fig. 2).
Using a rabbit anti-Hu EPO antiserum, enu-
meration of immunopositive cells confirmed the
Results increase in membrane eosinophils by rHu IL-5.
Compared to the number of eosinophils that
Eosinophil recruitment in cheek pouch mere- were found in untreated or denatured rHu IL-5
branes and peritoneum: Hamsters receiving membranes, substantially more cells were detec-
repetitive subcutaneous injections of rHu IL-5 ted in the membrane exposed to native rHu IL-5
(0.01 mg) to the right cheek showed a substantial (Fig. 3a,b,c). Cells reactive with anti-EPO were
increase in the number of eosinophils in the visible as discrete fluorescent ovals.
ipsilateral pouch membrane (Fig. 1). A statisti- Repetitive subcutaneous injections of rHu IL-5
cally significant rise in the number of membrane to the cheek pouch of hamsters resulted in a
eosinophils occurred by the second day. Sub- marked increase in the percentage of recoverable
sequent injections of rHu IL-5 further increased peritoneal eosinophils (Fig. 4). Rising from initial
the number of eosinophils and, by day 18, a 7- values of 12 + 2.3%, the percentage of peritoneal
fold increase in the number of eosinophils was eosinophils increased to 21 + 0.9% after 9 days
seen in treated membranes (Fig. 1). In contrast, and 34 + 2.3% after 11 days. Following a similar
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[] native rHu IL-5
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The suffusate clearance values of FITC-dx 150
obtained from these animals did not deviate sig-
nificantly from baseline during the 60 min time-
course (Fig. 5). Furthermore, the integrated
clearance value of FITC-dx 150 obtained from
the chronically rHu IL-5 treated animals was not
significantly elevated compared to that from
cheek pouch preparations exposed to topical
rHu It-5 for 5 min (Fig. 6; p > 0.05).
Discussion
In allergic inflammatory diseases, such as
atopic dermatitis and asthma, eosinophils have
been hypothesized to contribute to the obseeeed
tissue injury. There is increasing evidence that IL-
Day 5 is an important mediator for promoting eosi-
FIG. 2. Time-course of rHu Ik-5 induced eosinophilia in the con- nophil responses in these situations. While
tralateral cheek pouch membrane. Animals received repetitive effecting directed chemotaxis, mature peripheral
subcutaneous injections of either native or denatured rHu IL-5 as eosinophils exposed to recombinant IL-5 (rlL-5)
described in Materials and Methods. The contralateral cheek show an increase in their respiratory burst, an
pouch membrane was removed, fixed and processed for histolo-
gical evaluation. Eosinophils were enumerated as described in upregulation of adhesion receptors, augmented
Fig. 1. Data reported are the mean (#/HPF)-I-S.E.M. Sig- degranulato.ry events and increased in vitro survi-
24 26 nificance (*; p < 0.05) between treatments, for the given day, vability. Additionally, IL-5 has been docu-
was determined using the Mann-Whitney non-parametric test. mented, in vitro, to increase the production of
eosinophils from bone marrow cultures, umbili-
cal cord cells, and a number of immortal tumour
pattern of administration, denatured IL-5 did not cell lines.27-29 Combined, these studies suggest
increase the percentage of peritoneal eosinophils that IL-5 is a late-acting specific factor for eosino-
(Fig. 4). phil bone marrow production, release, directed
migration and activation.
Macromolecular clearance of FITC-dx I50 and However, few in vivo studies have been con-
intravital microscopy: To evaluate the acute ducted where rlL-5 has been directly adminis-
effects of rHu IL-5, the microcirculation of the tered. More often, studies investigating the in
hamster cheek pouch was surgically prepared vivo role of IL-5 on eosinophils have taken the
and topically challenged for 5 min with either form of administering monoclonal antibodies
bicarbonate buffer or rHu IL-5. Compared to (mAbs). Through the use of mAbs, researchers
bicarbonate buffer, the application of rHu IL-5 have shown that IL-5, exclusively, is important for
(0.1mg/ml, l ml) to the hamster cheek pouch the eosinophilia that is associated with allergic
preparation did not result in a significant lung eosinophilia, parasitic infections and episo-
increase in the clearance of FITC-dx 150. Fur- dic angio-oedema.2’
therrnore, the topical application of rHu IL-5 did While eosinophils normally populate the
not alter vessel diameters, cause muscle fascicula- hamster cheek pouch membrane, the recruitment
tions, or result in demonstrable leukocyte adhe- and activation of large numbers of eosinophils
sion over the 60 min time-course of by the cytokine IL-5 might result in the release of
experimentation, any number of inflammatory agents that induce
Animals were then treated with repetitive sub- oedema.4 This hypothesis is supported by the
cutaneous injections of rHu IL-5 (0.01 mg/animal; clinical presentation of capillary leak syndrome in
three times per week) to the cheek pouch for a cancer patients undergoing IL-2 treatment. Ele-
9-day time-course. During the microsurgical pre- vated plasma levels of IL-5 and the activation of
paration, no distinguishing alterations in the eosinophils have been associated with oedema
membrane or vascular bed were noted. Further- and morbidity in these patients.
5
more, throughout the stabilization period and the Our report conclusively demonstrates that
60 min time-course of the experiment, the repeated exposure to IL-5 can promote sub-
microcirculation of the cheek pouch showed no stantial recruitment of eosinophils to the cheek
visible fluorescent leakage sites, muscle fascicula- pouch membrane of the hamster. The local and
tions, or substantial alterations in vessel diameter, systemic bioactivity of repetitive subcutaneous
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FIG. 3. Immunofluorescent detection of ipsilateral membrane eosinophils. Original representative 18 day samples were at 160 x mag-
nification. For publication purposes photomicrographs were reduced. Coded samples from: (a) native rHu IL-5 treated; (b) denatured
rHu IL-5 treated; and (c) untreated membranes were incubated with rabbit anti-Hu EPO. Indirect immunofluorescence was conducted
using FITC-labelled anti-rabbit IgG. Primary incubation of samples with normal rabbit IgG did not result in fluorescent staining (data not
shown).
injections of rHu IL-5 in the hamster is sup-
ported by our findings that: (a) histological
examination of the underlying ipsilateral pouch
membrane revealed a significant increase in the
number of eosinophils; (b) less profound eosi-
nophilia occurred in the contralateral pouch
membrane; and (c) recoverable cells from peri-
toneal lavage were enriched in the percentage of
eosinophils. However, although evoking a promi-
nent eosinophilia, the repetitive administration of
IL-5 did not alter vascular permeability, leading us
to conclude that besides IL-5 other factors are
required to cause the activation and degranula-
tion of eosinophils under our experimental con-
ditions.
We have previously demonstrated that sub-
nanomolar concentrations of the four prominent
eosinophil granule proteins: major basic protein
(MBP), eosinophil cationic protein (ECP), eosi-
nophil derived neurotoxin (EDN) and eosinophil
peroxidase (EPO) have the capacity to increase
microvascular permeability in the hamster cheek
pouch preparation.
8 Therefore, even partial
degranulation of the recruited eosinophils should
have resulted in a substantial increase in the
clearance of FITC-dx 150. However, our immu-
nofluorescenc studies indicated that the recrui-
ted eosinophils had not degranulated. Based on
the discrete staining pattern with anti-EPO anti-
serum, this granule protein remained intracel-
lular. Because EPO is found in the matrix of the
specific granule, its presence within the cell indi-






FIG. 4. Effect of rHu IL-5 on peritoneal eosinophils. Animals
received repetitive subcutaneous injections to one cheek using
denatured or native rHu IL-5 over an 18 day time-course. At
appropriate days, the peritoneum was lavaged with saline as
described in Materials and Methods. Peritoneal cells were
washed and Cytospin preparations were made. At least 300
cells were counted and the percentage of eosinophils was deter-
mined. Unless otherwise noted, each day had three animals per
treatment (n.d. not done). Values reported are the mean -t-
S.E.M. Marginal significance (#; p=O.05) between treatments,






FIG. 5. Effect of rHu IL-5 based eosinophilia on the time-course
of clearance of FITC-dx 150. Animals received repetitive injec-
tions of rHu IL-5 (0.01 mg per injection) for 9 days. Cheek pouch
membranes were arranged for intravital microscopy and the
plasma clearance of FITC-dx 150 was monitored for 60 min.
cates that the three remaining proteins-MBP, ECP
and EDN were still contained there as well.
It is plausible that the IL-5 induced eosinophi-
lia present in the membranes represents a
primed system and subsequent treatment with an
appropriate agonist might provoke degranulation
of the recruited eosinophils. As a preliminary test
of this hypothesis, we treated one of the cheek








FIG. 6. Comparison of acute and chronic rHu IL-5 administration
on the clearance of FITC-dx 150. Cumulative clearance values
were determined throughout the 60 min time-course of the
experiment in animals receiving rHu IL-5, either 0.1 mg topically
for 5 min or 0.01 mg per injection over 9 days. No significant
difference between treatment groups was noted (p > 0.05).
pouch preparations with a sub-optimal challenge
(10-9M) of PAF. In this microcirculatory model,
this concentration of PAF is below the threshold
needed to increase the clearance of FITC-dx
150.36’37 Moreover, using isolated human eosino-
phils, 10-9M PAF is a potent degranulatory
agent.
38 After challenge, no increase in the
clearance of FITC-dx 150 was observed (data
not shown), suggesting that the system is not
overtly sensitive to stimulation or degranulatory
events.
The need for IL-5 bioactivity to cause the eosi-
nophilia was confirmed by treating with dena-
tured rHu IL-5 and failing to find a similar pattern
of eosinophilia, both locally and systemically.
Nevertheless, at the site of injection, within the
underlying membrane, a small but detectable
increase in the number of eosinophils was noted.
Because no effect was detected in the con-
tralateral membrane or in the peritoneal cell dif-
ferential, we believe that this small local increase
in eosinophils is probably due to the repetitive
injections of a foreign denatured protein. The
possibility that repetitive needle punctures (27
gauge) may have resulted in a fibrotic wound
healing condition, causing the recruitment of
eosinophils cannot be excluded.39 However, we
believe this to be an unlikely explanation for our
observations. In the wound healing models of
tissue eosinophilia, the cutaneous wounds are
substantially larger than that provoked by our
39 40 needle punctures. Furthermore, in our model
we are studying the underlying oral membrane
after the removal of the overlying, loose con-
nective aerolar tissue.
The capacity of IL-5 to direct selective eosino-
phil chemotaxis has been reported from in vitro
41 42 studies. Recent experiments also suggest thatIL-5 induced tissue eosinophilia
local production of IL-5 is responsible for eosi-
nophil recruitment after antigen challenge in
allergic individuals.4 The cellular signaling for
eosinophil chemotaxis is through the binding of
IL-5 to specific surface receptors on the mature
eosinophil leukocyte.
44 In our experimental
model, the selected and directed recruitment of
the eosinophils might be a result of the cells fol-
lowing a gradient in the administered IL-5, as the
molecule was carried out into the systemic circu-
lation. This hypothesis would also partially
explain the lack of tissue accumulation of the
eosinophils in the IL-5 transgenic animals. In this
latter case, IL-5 is constitutively produced by all
the T cells of the animal. Therefore, there is no
directed tissue recruitment of eosinophils, as
there is no specific gradient in IL-5.
In summary, our experiments document that
repetitive exposure to rHu IL-5 can selectively
recruit eosinophils to the hamster cheek pouch
membrane. However, eosinophilia per se does
not necessarily result in pathological alterations
of vascular functions. This lack of pathologic
sequelae in response to eosinophilia is consistent
with findings in transgenic mice where eosino-
philia is not, in general, associated with patho-
physiological consequences.45 However, it is in
contrast with the observations of eosinophilia
and IL-5 in the IL-2 induced capillary leak syn-
drome.35 Because the hamster cheek pouch
membrane microcirculation offers an accessible
vascular network that has been intensely studied
and responds to eosinophil granule proteins, it
may be useful for establishing the parameters
needed to elicit tissue damage by enhanced eosi-
nophil degranulation.
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